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Clinical benefit from palliative chemotherapy
in non-small-cell lung cancer extends to the elderly
and those with poor prognostic factors
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Summary The intention ofthis study was to identify the pretreatment characteristics predicting forthe survival, objective response and symptom
relief in patients with non-resectable, non-small-cell lung cancer (NSCLC) managed in the Lung Unit at the Royal Marsden Hospital. This
analyss induded 290 patients with advanced NSCLC generally treated with a cisplatin-based chemotherapy regimen in one of a series of trials.
Thirty-seven pretreatment variables, response and survival data were collected prospectvely and analysed using univariate and muftivanate
methods. By muttivariate analysis perforrance status, disease extent and pattem of metastases ak)ng with certain biocemnical features were
influential independent variables for survival, objective and symptom response. Older age was positively associated with objecive response
(P= 0.04). When the independent factors forsymptom response were used to group patients into prognostic categories, 30P480/o of patients with
an adverse set of factors had symptom relief. Similarly using the relative risk of death to subgroup the patient population, 54% of patients at high
risk of death (greaterthan 8.0), with a median survival of 2.5 months, had symptom relief. The data are consistent with other studies in identifying
the pretreatnent factors predicting for survival and objective response. Additionally, older age is positivety associated with objective response
and the majority of patents with the worst prognosis have symptom relief from treatment with chemotherapy.
Keywords: symptom relief; palliative chemotherapy; non-small-cell lung cancer; elderly patients
The prognosis of advanced inoperable non-small-cell lung cancer
is poor and the use of chemotherapy to palliate this disease
remains controversial. although evidence is accumulating that
demonstrates that its use is associated with symptom relief. a small
survival advantage and perhaps economic benefit (Jaakkimainen
et al. 1990: Cullen. 1993: Souquet et al. 1993: Ellis et al. 1995a:
Non-small Cell Lung Cancer Collaborative Group. 1995).
Platinum-based chemotherapy regimens. usually combined with
the vinca alkaloids. have resulted in reproducible objective
response rates ofthe order of30% (Veronesi et al. 1988: Luedke et
al. 1990: Donnadieu et al. 1991). A series ofretrospective analyses
of clinical trials ofchemotherapy in advanced NSCLC have iden-
tified a range of factors predicting for survival and response
(O'Connell et al. 1986: Fukuoka et al. 1991: Kawahara et al. 1991:
Weick et al. 1991: Shinkai et al. 1992: Paesmans et al. 1995). with
the intention of designing better randomized trials that might
detect only small survival improvements. Currently available
cytotoxic chemotherapy. however. is used as a palliative inter-
vention in advanced NSCLC. and it is therefore important to know
which pretreatment characteristics might influence the likelihood
of symptomatic benefit in addition to any influence on response
and survival.
Since 1990. we have prospectively generated a database of
patients with a diagnosis ofadvanced. inoperable NSCLC referred
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to the Lung Unit at the Royal Marsden Hospital. and we have
analysed the pretreatment variables for their influence on sympto-
matic response and objective response to chemotherapy. usually
cisplatin based, and survival in 290 patients treated in the context
of a senres ofphase H trials.
PATIENTS AND METHODS
The patients included in this analysis were all those with inoper-
able histologically or cytologically proven non-small-cell lung
cancer referred to the Lung Unit at the Royal Marsden Hospital
from 1990 to June 1995 and entered into one of a series of
chemotherapy trials.
The patient characteristics and pretreatment variables are shown
in Tables 1 and 2. Patients received chemotherapy according to
the following regimens: MVP (mitomycin C. vinblastine and
cisplatin) (Ellis et al. 1995a). 215 patients: MCF (mitomycin C.
cisplatin and 5-fluorouracil). 31 patients (Ellis et al. 1995b); zeni-
platin. 28 patients (data on file). Sixteen patients received other
regimens: carboplatin (high dose). one patient: carboplatin
(normal dose). one patient: ACE [Adriamycin (doxorubicin).
cyclophosphamide. etoposide]. one patient: topotecan. seven
patients (Mainwaring et al. 1997): oral etoposide. one patient:
mitoxantrone. one patient: MVC (carboplatin. methotrexate.
vinblastine). two patients: ifosfamide. one patient (Table 3).
Patients received supportive care as appropriate with steroids.
analgesia. pleural effusion drainage ± pleuradesis. radiotherapy
and counselling. Twenty-six patients had received palliative radio-
therapy (generally to lung. bone or CNS). less than 3 months (and
more than 1 week before) commencing chemotherapy. Fourteen
patients had previously been exposed to non-cytotoxic systemic
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Table 1 Patient charactenstics
Variable Group No. of patien (%)
All patients
Sex
Age (years)
Age (years)
Stage
Performance status
(ECOG)
Time from diagnosis to
chernotheapy
Previous treatment
Histoiogy
Chemoterapy
Chemotherapy
Male
Female
<60
.60
<40
40-49
50-59
60-69
>70
LimiteddlllA
ExtensiveIlV
0
1
2
3
< 3 months
3-5 months
6-11 monts
> 1 year
Surgery
No surgery
Radiotherapy
No radiotherapy
Lonidamine or tamoxifen
or monoclonal Ab or IP bleo
No previous cytotoxic drug Rx
Squamous
Adenocarcinoma
Large cell
Others
MVP
MCF
CL 286,558
Others
Combination chemotherapy
Single agent
Platinum based
Non-platinum based
290
189 (65)
101 (35)
162 (56)
128 (44)
17 (6)
52 (18)
93 (32)
92 (32)
36 (12)
103 (35)
187 (65)
30 (10)
196 (68)
40 (14)
10 (3)
193 (67)
40 (14)
29 (10)
28 (9)
18 (6)
272 (94)
59 (20)
231 (80)
15 (5)
275 (95)
80 (28)
149 (51)
28 (10)
33 (11)
215 (74)
31 (11)
28 (10)
16 (5)
249 (86)
41 (14)
278 (96)
12 (4)
therapy, generally in a series of pilot or phase I trials, as follows:
lonidamine, five patients: tamoxifen, four patients; ICR62 mono-
clonal antibody, three patients; CDP 671 monoclonal antibody.
two patients. One patient had received intrapleural bleomycin.
None ofthese agents was considered to influence the likelihood of
response to systemic chemotherapy.
Patients were generally seen every 3 weeks and chemotherapy
was continued usually to a maximum of six cycles if there was
evidence of symptomatic benefit, objective response and permis-
sible toxicity. Objective response was recorded according to stan-
dard criteria (Miller et al. 1981). Symptom response was recorded
as follows. Tumour-related symptoms were recorded at the start of
treatment under the following general headings: malaise, pain.
cough, dyspnoea or 'other' which was then specified. Symptoms
were then reassessed after each course of treatment with patients
asked to grade change in symptoms by a nurse specialist using
simple descriptive critenra as follows: (1) complete disappearance
of symptoms (CR); (2) good improvement of symptoms (PR): (3)
Table 2 Patient characteristics - addtional pretreatment vanables
Others variables examined Group
Symptoms Malaise
Pain
Cough
Dyspnoea
Haemoptysi
Other signs
Sites No. of involved lungs
Mediastinum
SvC
Pleura
Supraclavicular nodes
Other nodes
Skin
Liver
Bone
CNS
Adrenal
Other sites
Chemistry Calcium
Albumin
Sodium
Potassium
Alkaline phosphatase
Alanine transaminase
Gamma GT
Haematology Haemogkbin
White cell count
Platelets
minor or no change of symptoms (NC); (4) worse (PD).
Progression of any tumour-related symptom was recorded as an
overall progression of symptoms.
Data collection and analysis
Demographic, laboratory, disease and symptom data were
collected prospectively and entered onto the Lung Unit database
and in June 1995 were analysed for objective response. sympto-
matic response and survival. For the purpose of analysis. each of
the pretreatment biochemistry and haematological variables was
used to divide patients into groups based on the normnal ranges of
the variables. Response duration and survival were measured from
the date of initiation of chemotherapy continued until tumour
progression, the date of last follow-up or death. All survival plots
were based on Kaplan-Meier limit estimates. No deaths were
censored in the survival analysis. All variables were tested for
prognostic significance on objective and symptomatic response
in a univariate analysis using the chi-squared or Mann-Whitney
test with trend. A multivariate logistic regression analysis was
performed subsequently to detect factors independently associated
with response (Breslow and Day. 1980). Variables were added to
the model using a step-up maximum-likelihood ratio method. The
relative likelihood of response between different patient groups
was calculated for all the significant variables. The same variables
were also tested for their prognostic influence on survival in a
univariate analysis using the life-table method and log-rank test.
The multivariate Cox's proportional hazards model (Cox. 1972)
was used to test for the independent prognostic significance of
variables. A step-up maximum partial likelihood procedure was
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used and the relative risks of death between the patient groups
were calculated for all significant variables.
RESULTS
The distribution ofthe clinical characteristics in the 290 patients is
shown in Table 1. The age range was 28-78 years and 44% of
patients were over 60 years: 65% of the patients were male: 90%
of patients had an initial performance status of 1 or less: 51% of
patients had adenocarcinoma: 28% had squamous cell and 10%
had large cell, with 11% others (bronchioalveolar or anaplastic
non-small-cell lung cancer). Thirty-five per cent ofpatients had no
extrathoracic disease. and the majority of these had mediastinal
lymphadenopathy or direct mediastinal and thoracic organ inva-
sion. Ofthe patients with metastatic disease. 9% had skin involve-
ment: 21-'% had hepatic involvement; 32% had bone involvement:
9% had CNS involvement: the adrenal(s) was involved in 9% and
both lungs were involved in 315%. Ninety-two patients (32%) had
received prior therapy. with either surgery (6%), radiotherapy
(20%) or chemotherapy (5%). Sixty-seven per cent of patients
commenced treatment in a Lung Unit chemotherapy protocol
within 3 months ofdiagnosis, and 9% underwent such a treatment
more than 1 year after diagnosis. Forty-seven patients received
palliative radiotherapy within 1 week of. and up to 3 months after,
starting chemotherapy.
Objective response
Thirty-seven pretreatment factors (Tables 1 and 2) were included
in the univariate analysis for objective response. Only three were
found to be associated with objective response. Combination vs
single-agent chemotherapy. limited vs extensive disease and
performance status (ECOG) each significantly predicted for a
response (P < 0.05). In the multivariate analysis (Table 4). perfor-
mance status had independent significance for predicting response
(P = 0.006). Additionally. one lung, as opposed to both lungs.
involved predicted for response (P= 0.005). Increasing age
positively predicted for response (P = 0.04).
Symptom response
Of the patients. 270 were evaluable for symptom response. In the
univariate analysis. male sex. disease extent (limited vs extensive)
(P < 0.05), performance status (P < 0.05) and the absence ofprior
radiotherapy (P < 0.05) were all positive predictors for response.
The absence of skin involvement (P < 0.05) and the absence of
CNS involvement (P < 0.05) were also positive predictors of
response. Raised calcium (corrected > 2.6 mmol 1-1) was a
predictor for symptomatic response (P < 0.05). In the multivariate
analysis for symptom response. the variables analysed were those
used in the objective response analysis (Table 4). excluding indi-
vidual symptoms. CNS involvement (P = 0.007). poor perfor-
mance status (P = 0.004). skin involvement (P = 0.03) and
bilateral lung involvement (P = 0.03) were independent adverse
predictors for symptomatic response to chemotherapy (Table 4).
The multiplicative nature of relative likelihoods enabled the
calculation of a prognostic index. for each patient. based on the
significant independent predictors of symptom relief. This index
was used to divide patients into prognostic groups with differing
likelihoods of symptom response. For simplicity of calculation in
the clinic, an equivalent definition of the prognostic groups used
the number of poor prognostic factors that they had, as follows:
performance status 2 scores 1. performance status 3 scores 2:
involvement of CNS scores 2: involvement of skin scores 2:
involvement of both lungs scores 1 (Table 5). This analysis indi-
cates that 30-48% of patients with an adverse set of prognostic
factors for symptom response will yet have such a response.
Survival
In the univariate analysis. male sex (P < 0.025). extensive disease
status (P < 0.005). low performance status (P < 0.005) and
previous radiotherapy (P < 0.01) predict for poorer survival.
Similarly. involvement ofboth lungs (P < 0.05). skin involvement
(P < 0.005), bone involvement (P < 0.005) and adrenal involve-
ment (P < 0.05) have poorer survival. The following biochemical
variables also predicted forpoorsurvival: serum albumin < 35 g 1-1
Table 3 Chemotherapy regimens
Mitomyon C
Vinbiastine
Cispiatin
Mitomycin C
Cisplatin
5-Ruorouracl
Adriarnycin (doxorubicin)
Cycoposphamide
Etoposide
Carboplatin
Methotrexate
Viblastine
145 mg m-2over 90 min every 21 days
0.5 mg rn-2 by continuous 21-day infusion every 28 days
50 mg bd for 7 days
10mg m -2
5 g rn-2 over 6 h every 21 days
8 mg r-2 day 1 (given on alternate courses)
6mg mr-2 day 1 q 3 weekly
50 mg mr-2 i.v. day 1 q 3 weeldy
8 mg m-2 day 1 (given on alternate courses)
75 mg rn-2 day q 4 weeldy
200 mgr-2 continous i.v. infusion daily via a
Hickman line
50 mg rn-2 i.v. day 1
750 mg r-2 i.v. day 1
100 mg r-2 i.v. days 1-3
300 mg rn-2 i.v.
30 mg rn-2 i.v.
6 mg m-2 i.V.
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MVP
MCF
ACE
MVC
Zeniplatin
Topotecan
Oral etoposide
Mitoxantrone
ffosfamide
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Table 4 Mutivanate analysis of (A) objectve response. (B) symptomatic
response and (C) survival
A
Variable Relatv likelihood of esponse Signifiance
Performance status
0 1.0
1 0.52 (0.33-0.83) P= 0.006
2 0.27 (0.11-0.68)
3 0.14 (0.03-0.56)
Lungs
One 1.0
Both 0.37 (0.18-0.79) P= 0.005
Age (years)
<49 1.0
50-59 1.30 (1.01-1.67) P= 0.04
60-69 1.68 (1.02-2.77)
70-79 2.18 (1.03-4.61)
B
Variable Relati likelihood of response Significance
Performance status
0/1 1.0
2 0.58 (0.26-1.27) P = 0.004
3 0.10(0.02-0.41)
CNS
Not involved 1.0
Involved 0.18 (0.06-0.50) P= 0.007
Skin
Not involved 1.0
Involved 0.52 (0.10-0.78) P= 0.03
Lungs
One 1.0 (1.02-2.77)
Both 0.35 (0.23-0.90) P = 0.03
C
Variable Relave risk of death Significace
Performance status
0 1.0
1 1.71 (1.36-2.18) P<0.0001
2 2.93 (1.82-4.73)
3 5.02 (2.45-10.3)
Alk phosphate
Normal 1.0
1-2 x Normal 1.63 (1.30-2.04) P< 0.0001
>2 x Normal 2.65 (1.69-4.15)
Stage
Intrathoracic 1.0
Extrathoracic 1.91 (1.39-2.63) P< 0.0001
Albumin
>35 1.0
30-35 1.34 (1.07-1.67) P= 0.02
< 30 1.79 (1.15-2.78)
Sidn
Not involved 1.0
Involved 1.85 (1.12-3.05) P= 0.02
(P < 0.005). sodium < 135 mmol 1-' (P < 0.005). alkaline phos-
phatase elevated more than two times the normal level (P <0.005).
alanine transaminase elevated more than two times the normal
level (P < 0.025). haemoglobin < 13 g (P < 0.05) and reduced
Table 5 Symptom response by prognostc group
Score Patients Symptomatic !esponse % Median survival
(rnge) (monts)
0 150 83 (77-89) 7
1 72 76 (66-6) 6
2 44 48 (33-63) 2
3+ 10 30 (2-58) 3
white cell count <8.0 x 10 (P < 0.005). In the multivariate
analysis (Table 4). poorerperfonnance status (P < 0.001). alkaline
phosphatase elevated more than two times the normal level
(P < 0.001). extensive disease (P < 0.001). albumin < 35 g 1-'
(P = 0.01) and skin involvement (P < 0.025) were all predictors
ofpoorer survival.
For a patient with two or more poor prognostic features. the
relative risks ofdeath are multiplicative. The overall risk ofdeath.
relative to a patient with no poor prognostic features. was calcu-
lated for each patient and was used to group the patients into prog-
nostic groups. Patients with an overall risk ofdeath ofless than 4.0
had the best prognosis. with a median survival of 9 months. an
objective response rate of37% and a symptomatic response rate of
78%. Those patients with a relative risk of death between 4.0 and
8.0 had an intermediate prognosis. with a median survival of 6
months. an objective response rate of 39% and a symptomatic
response rate of 77%. Those with the worst prognosis and a rela-
tive risk of death greater than 8.0 had a median survival of 2.5
months, an objective response rate of 13% but a symptomatic
response rate of54% (Table 6).
DISCUSSION
Consistent with previous reports on prognostic factors in advanced
NSCLC (Albain et al. 1991: Fukuoka et al. 1991: Paesmans et al.
1995). multivariate analysis in this trial identified performance
status as a key factor adversely influencing survival. as was an
elevated alkaline phosphatase. the presence of extrathoracic
disease and the presence of skin metastases. All of these factors
had been found to adversely influence survival in other studies but.
other than performance status, they are not reproducibly influen-
tial. This also holds for the factors influencing objective response.
In this study. again. poor performance status adversely influenced
the likelihood of a response. as did the presence of bilateral lung
involvement. Increasing age was, perhaps surprisingly. found to
positively predict for response. This positive influence of age on
outcome to chemotherapy in advanced NSCLC was also detected
by Albain et al (1991). when age was found to positively predict
for increased survival. Furthermore. in our study. by multivariate
analysis. age had no influence. either positive or negative. on
symptom reliefor survival.
In our multivariate analysis. poorer performance status, the
presence of CNS. skin and bilateral lung involvement adversely
predicted for symptomatic response. However. when patients were
grouped by the number of factors adversely predicting symptom
response. even those with the highest score still had a 30% proba-
bility of a symptomatic response.
Taking together the factors identified by multivafiate analysis to
influence objective response, symptomatic response and survival.
those patients with the greatest relative risk of death (> 8.0) had a
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Table 6 Survival and response by prognostic group
Relative risk No of Medan Obci Symptomatic
of death patients survival (mnths) response (%) response (%)
Good prognosis <4.0 122 9 37 (28-45) 78 (70-6)
Medium prognosis 4.0-8.0 88 6 39 (28-49) 77 (68-86)
Poor prognosis > 8.0 60 2.5 13 (5-22) 54 (41-67)
very poor mean survival of2.5 months and a very small chance of
objective response (13%) but still had a reasonable probability ofa
symptomatic response (54%), with significant alleviation in all the
recorded symptoms.
Accurate quantification of the symptom relief benefit resulting
from chemotherapy can only be provided by a placebo-controlled
randomized trial in which all patients receive optimal supportive
care. Clearly, in this study, supportive care therapies will have
influenced symptomatology. However, given that the vast majority
of patients are established on appropriate supportive care at
presentation, it seems likely that these measures would dilute only.
rather than fully account for. symptom relief associated with
chemotherapy.
An important finding in this analysis is that age is not an adverse
factor in the palliation of NSCLC. and yet such treatment is
usually reserved for younger age groups. The upper age limit in
only four of eight authoritative trials of chemotherapy vs
supportive care for patients with advanced NSCLC extended to 75
years (reviewed in Shepherd. 1994), and the average ofthe median
ages in this group oftrials was approximately 60 years. There was
no evidence from these trials that the elderly fared less well with
chemotherapy. The impact of age as a prognostic factor for
survival and response in advanced NSCLC has been analysed in a
series of recent reports totalling 4516 patients (O'Connell et al.
1986; Albain et al, 1991: Fukuoka et al, 1991: Kawahara et al,
1991; Shinkai et al, 1992; Paesmans et al, 1995). In one of these.
the South West Oncology Group analysed a database of 2531
patients with stage IV NSCLC (Albain et al, 1991) and found by
multivariate analysis that age greater than 70 years was in fact a
significant independent positive predictor for survival (P = 0.02).
In the remainder of these studies, age had no influence by multi-
variate analysis. Given that more that 50% of patients with
advanced NSCLC are over the age of 65 years and the growing
elderly population, palliative treatment of the elderly with this
disease is likely to be a growing issue, and our data indicate that
such patients should not be excluded from palliative chemotherapy
trials on the grounds ofage alone. Performance status, irrespective
ofage, would seem to be a much more appropriate basis for treat-
ment selection.
In summary, this analysis of a large database of patients treated
in a series of clinical trials demonstrates that even patients with
the worst outlook are likely to benefit from palliation with
chemotherapy and that age is not an adverse prognostic factor.
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